MustGrow Biologics Shareholders Approve Plans

MustGrow Biologics (TSE:MGRO) has released an update.

MustGrow Biologics Corp. successfully conducted its 2024 annual shareholder meeting, resulting in the unanimous re-election of director nominees and the approval of Ersnt & Young LLP as auditors with authority over their remuneration. Shareholders also reapproved the Company’s Omnibus Plan, pending final TSX Venture Exchange sanction. The company continues to innovate in organic biocontrol and biofertility, collaborating with global partners to offer sustainable alternatives to synthetic chemicals in agriculture.

For further insights into TSE:MGRO stock, check out TipRanks’ Stock Analysis page.